935 related articles for article (PubMed ID: 19261294)
1. Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes?
Samuelov-Kinori L; Kinori M; Kogan Y; Swartzon M; Shalev H; Guy D; Ferenidou F; Mashav N; Sadeh B; Atzmony L; Kliuk-Ben-Basat O; Steinvil A; Justo D
J Electrocardiol; 2009; 42(4):353-357.e1. PubMed ID: 19261294
[TBL] [Abstract][Full Text] [Related]
2. The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias.
Topilski I; Rogowski O; Rosso R; Justo D; Copperman Y; Glikson M; Belhassen B; Hochenberg M; Viskin S
J Am Coll Cardiol; 2007 Jan; 49(3):320-8. PubMed ID: 17239713
[TBL] [Abstract][Full Text] [Related]
3. Drug-induced torsades de pointes in patients aged 80 years or more.
Paran Y; Mashav N; Henis O; Swartzon M; Arbel Y; Justo D
Anadolu Kardiyol Derg; 2008 Aug; 8(4):260-5. PubMed ID: 18676301
[TBL] [Abstract][Full Text] [Related]
4. Takotsubo cardiomyopathy as a potential cause of long QT syndrome and torsades de pointes.
Ghosh S; Apte P; Maroz N; Broor A; Zeineh N; Khan IA
Int J Cardiol; 2009 Aug; 136(2):225-7. PubMed ID: 18617280
[TBL] [Abstract][Full Text] [Related]
5. Long-QT syndrome and torsades de pointes in a patient with Takotsubo cardiomyopathy: an unusual case.
Mahida S; Dalageorgou C; Behr ER
Europace; 2009 Mar; 11(3):376-8. PubMed ID: 19095686
[TBL] [Abstract][Full Text] [Related]
6. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
Arbel Y; Swartzon M; Justo D
Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
[TBL] [Abstract][Full Text] [Related]
7. Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation.
Kirchhof P; Franz MR; Bardai A; Wilde AM
J Am Coll Cardiol; 2009 Jul; 54(2):143-9. PubMed ID: 19573731
[TBL] [Abstract][Full Text] [Related]
8. Acquired long QT syndrome from stress cardiomyopathy is associated with ventricular arrhythmias and torsades de pointes.
Madias C; Fitzgibbons TP; Alsheikh-Ali AA; Bouchard JL; Kalsmith B; Garlitski AC; Tighe DA; Estes NA; Aurigemma GP; Link MS
Heart Rhythm; 2011 Apr; 8(4):555-61. PubMed ID: 21146632
[TBL] [Abstract][Full Text] [Related]
9. Drug-induced long QT syndrome and torsade de pointes.
Morissette P; Hreiche R; Turgeon J
Can J Cardiol; 2005 Aug; 21(10):857-64. PubMed ID: 16107909
[TBL] [Abstract][Full Text] [Related]
10. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
Abi-Gerges N; Philp K; Pollard C; Wakefield I; Hammond TG; Valentin JP
Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
[TBL] [Abstract][Full Text] [Related]
11. Magnitude of QT prolongation associated with a higher risk of Torsades de Pointes.
Lin YL; Kung MF
Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):235-9. PubMed ID: 19145580
[TBL] [Abstract][Full Text] [Related]
12. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE
Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938
[TBL] [Abstract][Full Text] [Related]
13. [Takotsubo cardiomyopathy associated with torsades de pointes and long QT interval: a case report].
Okada T; Miyata S; Hashimoto K; Maie K; Mochizuki S
J Cardiol; 2007 Jul; 50(1):83-8. PubMed ID: 17685032
[TBL] [Abstract][Full Text] [Related]
14. Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and torsade de pointes in the general surgical population?
Nuttall GA; Eckerman KM; Jacob KA; Pawlaski EM; Wigersma SK; Marienau ME; Oliver WC; Narr BJ; Ackerman MJ
Anesthesiology; 2007 Oct; 107(4):531-6. PubMed ID: 17893447
[TBL] [Abstract][Full Text] [Related]
15. Arrhythmias associated with fluoroquinolone therapy.
Falagas ME; Rafailidis PI; Rosmarakis ES
Int J Antimicrob Agents; 2007 Apr; 29(4):374-9. PubMed ID: 17241772
[TBL] [Abstract][Full Text] [Related]
16. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?
Mayet S; Gossop M; Lintzeris N; Markides V; Strang J
Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918
[TBL] [Abstract][Full Text] [Related]
17. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.
Pearson EC; Woosley RL
Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):747-53. PubMed ID: 15918160
[TBL] [Abstract][Full Text] [Related]
18. Two cases of torsades de pointes associated with Takotsubo cardiomyopathy as the second insult.
Yamada Y; Tani T; Homma M; Saito S
J Electrocardiol; 2011; 44(6):806-9. PubMed ID: 21524756
[TBL] [Abstract][Full Text] [Related]
19. Prolonged QT interval and torsades de pointes associated with atazanavir therapy.
Ly T; Ruiz ME
Clin Infect Dis; 2007 Mar; 44(6):e67-8. PubMed ID: 17304444
[TBL] [Abstract][Full Text] [Related]
20. Torsades de pointes related to transient marked QT prolongation following successful emergent percutaneous coronary intervention for acute coronary syndrome.
Kawabata M; Hirao K; Takeshi S; Sakurai K; Inagaki H; Hachiya H; Isobe M
J Electrocardiol; 2008; 41(2):117-22. PubMed ID: 18328336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
